Lixisenatide is a novel GLP-1 receptor agonist for the treatment of type 2
INTRODUCTION
Globally, effective strategies for the clinical management of type 2 diabetes mellitus (T2DM) are receiving urgent attention as the world's T2DM population is nearly 400 million.
In Asia, the unprecedented rise in the prevalence of T2DM is particularly alarming. For instance, in China, the prevalence of T2DM increased from 3.2% in 1996 to ca. 9.7% in 2013, with the Chinese T2DM population at nearly 100 million, which represents approximately a quarter of the world's diabetic population [1, 2] .
Currently there is genuine concern about the extent of poor glycemic control in a large portion of the Asian T2DM population; for instance, recent evidence has shown that approximately two-thirds of patients in China who are treated with oral antidiabetic drugs (OADs) do not achieve the glycated hemoglobin (HbA1c) targets of B6.5 or B7% [3] [4] [5] .
Patients from East Asia with T2DM share common pathophysiologic characteristics, which are distinct from those of their European counterparts. In East Asian countries diabetes occurs at a much lower BMI than elsewhere in the world [6] , and the majority of East Asians with prediabetes have impaired glucose tolerance as opposed to impaired fasting glucose [7] . Another feature characterizing T2DM in Asian populations is the tendency to develop young-onset diabetes.
Studies conducted in different East Asian populations have found a mean age of diagnosis of T2DM typically around 50 years [8] . Impaired beta cell function plays an important role in the pathogenesis of diabetes in Asians, especially in those who are not overweight or have a positive family history.
Importantly, HbA1c values seem to be higher among Asians than Europeans, which is likely related to genetic similarities [9] . In addition to shared genetic and pathophysiological characteristics, East Asians have similar dietary habits. Therefore, a common treatment strategy for this population is indicated.
Currently in East Asia, patients with T2DM are commonly prescribed metformin/sulfonylurea, and the initiation of insulin therapy is often delayed [4, 5] . Because inadequately controlled T2DM can give rise to serious, irreversible medical complications, there is thus an urgent need to identify alternative treatment strategies that would improve glycemic control in the East Asian T2DM population.
Glucagon-like peptide-1 (GLP-1) receptor agonists increase insulin release, suppress glucagon secretion, and delay gastric emptying, which has been shown to be an effective strategy for improving glucose control in T2DM [10] . Furthermore, GLP-1 agonists are associated with a reduction in HbA1c levels, a low incidence of hypoglycemia, and a reduction in body weight [10] . GLP-1 receptor agonists are generally well tolerated, and side effects are mainly limited to mild gastrointestinal disturbances in a relatively small proportion of patients.
Lixisenatide is a novel, once-daily prandial GLP-1 receptor agonist for the treatment of T2DM [11] [12] [13] [14] [15] [16] . Its efficacy has been assessed across the full spectrum of the natural history of T2DM in a series of lixisenatide phase 3 studies that were included in the GetGoal study 
METHODS

Data Sources
To identify relevant clinical studies, we performed a manual search on ClinicalTrials.gov. Firstly, we searched for lixisenatide phase 3 studies from the GetGoal programme. The terms used in the search were ''phase 3'', ''lixisenatide'', and ''GetGoal'' and a total of 13 studies were identified. Secondly, we also searched on ClinicalTrials.gov and pubmed.gov to make sure study primary results had been published previously. Thirdly, we further narrowed down to studies which had enrolled Asian patients and evaluated lixisenatide as an add-on treatment to OADs and compared with placebo. The terms used in this search were ''Asian'' and ''OAD'' and ''placebo controlled''. Five studies were identified after this three-step search.
Analysis Design
The five randomized, placebo-controlled phase Table 1 for information on the individual studies). Briefly, GetGoal-M (NCT01169779) assessed the efficacy and safety of lixisenatide as an adjunct to metformin in patients with T2DM not adequately controlled with metformin. ITT intent-to-treat
GetGoal-F1 (NCT00713830) assessed the efficacy and safety of four treatment schedules with lixisenatide-a one-step or two-step dose escalation, lixisenatide once daily for 12 weeks as a one-step dose increase (10 lg for 2 weeks, then 20 lg) or two-step dose increase (10 lg for 1 week, 15 lg for 1 week, then 20 lg)-as an adjunct to metformin in patients with T2DM not adequately controlled with metformin.
GetGoal-P (NCT00763815) assessed the efficacy and safety of lixisenatide as an adjunct to pioglitazone in patients with T2DM not adequately controlled with pioglitazone. GetGoal-S (NCT00713830) assessed the efficacy and safety of lixisenatide as an adjunct to sulfonylurea in patients with T2DM not adequately controlled with sulfonylurea, and GetGoal-M-Asia (NCT01169779) assessed the efficacy and safety of lixisenatide in Asian patients with T2DM inadequately controlled by metformin (with or without sulfonylurea).
For the meta-analysis, the data on Asian patients included in the five GetGoal studies were extracted, amalgamated, and analyzed according to the protocol of the meta-analysis. The GetGoal programme was a series of phase 3, randomized, placebo-controlled trials conducted at centers across the globe. All studies were sponsored by Sanofi.
Inclusion Criteria
Only GetGoal studies that included Asian adults (men and women) with a confirmed diagnosis of T2DM (as defined by the World Health Organization, WHO) at least 1 year prior to study entry were eligible for inclusion in the meta-analysis. All patients had inadequate glycemic control (HbA1c levels C7%) despite an established regimen of OADs and were in the intent-to-treat populations. In all of the included studies, patients were randomly assigned to either lixisenatide or placebo as an adjunct to their usual OAD(s), and they self-administered the study drug. The OADs that were allowed in the studies included in this meta-analysis were either metformin (1.0-1.5 mg/day) ± sulfonylurea (at least half of the maximum recommended dose as per the package insert) or pioglitazone (at least 30 mg/day).
Endpoints
The primary endpoint of this meta-analysis Table 2 , and the main findings of the individual studies included in the meta-analysis with regard to HbA1c (percentage reduction), number of patients who achieved HbA1c targets of B6.5% or B7%, 2-h PPG, and safety are listed in Tables S1-4 in the supplementary material.
Statistical Methods
All meta-analyses were performed using RevMan, version 5. Standard meta-analytic techniques were applied to assess the overall outcome measures using a random-effects model with an inverse variance method to determine weighted mean differences with 95% confidence intervals (CIs) 
RESULTS
In total, 883 Asian patients with T2DM were available from the five GetGoal studies for inclusion in the meta-analysis. All of the patients had inadequate glycemic control (HbA1c levels C7%) on an established regimen of OADs (metformin ± sulfonylurea or pioglitazone). Of the 883 patients, 536 were assigned to lixisenatide and 347 to placebo as an adjunct to the patients' established OAD regimen. The demographics of the analysis populations for the meta-analysis are reported in Table 3 . The mean (SD) value of age, BMI, weight, HbA1c, and FPG at baseline, and the percentages of male patients were well balanced between two treatment groups.
HbA1c %
Compared with placebo, lixisenatide 20 lg once daily as an adjunct to an established OAD regimen significantly reduced HbA1c from baseline to week 24 in patients with inadequate glycemic control (weighted, total mean difference -0.57%; P = 0.002; Table 4 ). The potential heterogeneity of the primary endpoint was high (I 2 = 79%), but this was accommodated by the randomized-effects model.
Number (%) of Patients Achieving HbA1c
Targets of £7%
Significantly more patients in the lixisenatide versus the placebo treatment group achieved the HbA1c targets of B7% (49.1% vs. 28.4%, P = 0.003) ( Table 5 ). The odds ratios (ORs) for HbA1c B7% were 0.18 (0.06, 0.57, random-effects model).
Two-hour PPG
Two-hour PPG was measured in three of the five GetGoal studies only (GetGoal-M-Asia, GetGoal-M, and GetGoal-S).
Overall, lixisenatide was superior to placebo in lowering 2-h PPG at the end of the 24-week treatment period (weighted, total mean difference -5.50 mmol/l, P = 0.0005). Table 6 shows the change in 2-h PPG for lixisenatide versus placebo for all the treatment groups. The potential heterogeneity for the primary endpoint was relatively high (I 2 = 89%), but this was accommodated using a random-effects model. Table 8 ).
FPG
Lixisenatide was superior to placebo in lowering FPG (P\0.0001). The mean difference in FPG between the lixisenatide and placebo groups at the end of the 24-week treatment period was -0.51 mmol/l (-0.76, -0.26; random-effects model).
Change in Body Weight
Patients treated with lixisenatide generally had a stable body weight with a trend towards a decrease in body weight at the end of the 24-week treatment period [mean difference between groups -0.29 kg (-0.60, 0.01), both fixed and random-effects models]. Table 4 Forest plot for meta-analysis of least-squares mean difference between lixisenatide plus an OAD regimen and placebo plus an OAD regimen in terms of change in HbA1c (mITT population) 
HbA1c Reduction
Our meta-analysis found that, compared with placebo, lixisenatide, on average, reduced HbA1c by 0.57% after a 24-week treatment period. This signifies a clinically meaningful improvement in glycemic control in Asian patients with T2DM who were inadequately controlled with an established OAD regimen.
In the GetGoal-S study, which enrolled 859 patients of mixed ethnic origin (ca. 45% of them were of Asian origin), the mean baseline HbA1c level was 8.2-8.3%, and the magnitude of the HbA1c reduction was 0.74%. This was more than double that reported in the GetGoal-M-Asia study, which enrolled 391
Asian patients (90% of them were Chinese) in China, Malaysia, Thailand, and Hong Kong [17, 18] . The mean baseline HbA1c of patients in that study was relatively low (7.85-7.95%), and the mean HbA1c reduction was considerably lower than that in other similar
GetGoal studies that enrolled cohorts of mixed ethnic origin. The mean reduction in HbA1c in the present meta-analysis was greater than that reported in the GetGoal-M-Asia study (-0.36%). In our meta-analysis, the mean baseline HbA1c for the lixisenatide and placebo groups was 8.2% and 8.1%, respectively. Previous studies with GLP-1 receptor agonists showed that higher baseline HbA1c levels correlate with greater reductions in HbA1c [19] [20] [21] [22] [23] .
The results of our meta-analysis therefore provide consolidated evidence for the value of lixisenatide in achieving glycemic control in Asian patients with T2DM who do not meet target HbA1c values despite an established OAD regimen. Table 6 Forest plot for meta-analysis of least-squares mean difference between lixisenatide plus an OAD regimen and placebo plus an OAD regimen in terms of change 
SE standard error
Antidiabetic drugs that target GLP-1 are promising therapeutic options for Asian T2DM patients and it is postulated that GLP-1 receptor agonists increase glucose uptake, which, in turn, improves peripheral glucose utilization and measures of beta cell function [24, 25] .
Two-hour PPG Reduction
The main antidiabetic effect of lixisenatide as a prandial GLP-1 receptor agonist is to delay gastric emptying, which, in turn, controls PPG excursions [10] . Our meta-analysis reported a large reduction in 2-h PPG (-5.5 mmol/l) after the 24-week treatment with lixisenatide, which was significantly better than that of the placebo group (weighted, total mean difference -0.57%; P = 0.0005). PPG control is a fundamental component of glycemic control in Asian T2DM because PPG excursions are thought to be more pronounced in Asians than in Westerners with T2DM [9, 26] . These In general, Asian individuals develop T2DM at a lower BMI than Westerners, and this could explain the generally lower mean body weight of the Asian cohort in our meta-analysis [23] .
Nonetheless, in clinical practice, Asian individuals with T2DM do achieve high body weights and high BMIs, and these patients will most likely experience a reduction in body weight when treated with lixisenatide, similar to that of cohorts with a higher mean body weight in other GetGoal studies.
Safety
Although the incidence of TEAEs was higher in the lixisenatide than in the placebo group, the individual studies that were included in this meta-analysis showed that lixisenatide is generally well tolerated and the adverse events mostly mild to moderate in intensity. GLP-1 receptor agonists have a generally safe profile, and lixisenatide's safety results are consistent with that of other GLP-1 receptor agonists [6] .
Limitations
Observation can alter the behavior of both patients and physicians involved in clinical trials, and this may influence outcome measures, i.e., patients included in this meta-analysis were generally compliant with study protocols, and this may well not reflect real-world circumstances. For instance, in one of the GetGoal studies included in the meta-analysis, a relatively large placebo effect was observed in HbA1c, which is likely due to better patient compliance to diet and lifestyle changes because of more individualized care that is associated with study enrollment [17] .
CONCLUSIONS
In the present meta-analysis, lixisenatide as an adjunct therapy was superior to placebo in lowering both HbA1c and 2-h PPG levels of Asian patients with T2DM who were inadequately controlled with an established regimen of OADs. A 24-week treatment period with lixisenatide resulted in a reduction of 0.57% in mean HbA1c and a large reduction in 2-h PPG (-5.5 mmol/l). Patients in the lixisenatide treatment group were significantly more likely than those in the placebo group to achieve HbA1c B7% and PPG targets. Lixisenatide is generally well tolerated and the adverse events mostly mild to moderate in intensity. Taken together, lixisenatide as an adjunct therapy has clinical application in Asian patients with T2DM who are inadequately controlled with OADs.
